Second-trimester screening test for open neural tube defects. Order this test for PREGNANT FEMALE patients only. For males or non-pregnant females, refer to Alpha Fetoprotein, Serum (Tumor Marker) (0080428).
Quantitative Chemiluminescent Immunoassay
Specimen must be drawn between 14 weeks, 0 days and 24 weeks, 6 days gestation.
Serum Separator Tube (SST) or Plain Red.
Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Plasma. Hemolyzed specimens.
Submit with Order: Patient's date of birth, current weight, due date, dating method (US, LMP), number of fetuses present, patient's race, if the patient was diabetic at the time of conception, if there is a known family history of neural tube defects, if the patient is currently smoking, if the patient is taking valproic acid or carbamazepine (Tegretol), if this is a repeat sample, and the age of the egg donor if an in vitro fertilization.
After separation from cells: Ambient: 72 hours; Refrigerated: 2 weeks; Frozen: 1 year (Avoid repeated freeze/thaw cycles.)
Refer to report.
This test is used to screen for fetal risk of Open Neural Tube Defect (i.e., spina bifida).
|Component Test Code*||Component Chart Name||LOINC|
|0080241||Estimated Due Date||11778-8|
|0080918||MoM for AFP||20450-3|
|0080920||Maternal Screen Interpretation||49586-1|
|0080924||Insulin Req Maternal Diabetes||44877-9|
|0080925||Family Hx Neural Tube Defect||8670-2|
|0080927||Number of Fetuses||11878-6|
|0080932||Maternal Age At Delivery||21612-7|
|3000263||Gestational Age Calculated at Collection||18185-9|
- AFP Maternal Screening
- AFP Neural Tube Defects
- Maternal Screening, AFP Single Marker